文献速递消化系统肿瘤

FOLFIRINOX联合聚乙二醇重组人透明质酸酶对比FOLFIRINOX单药治疗转移性胰腺腺癌的IB/II期随机研究:SWOG S1313

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
PubMed 文献 · J Clin Oncol · 2019-02-28

在未经治疗的转移性胰腺癌患者中,IB期确定PEGPH20每2周3 µg/kg为II期剂量;II期随机分配138例至mFOLFIRINOX联合PEGPH20组或mFOLFIRINOX单药组,主要终点为总生存期。因中期无效分析显示联合组OS风险比2.07 favoring对照臂而提前关闭入组;联合组治疗相关3-4级毒性显著增加(OR 2.7,95%CI 1.1-7.1),中位OS为7.7个月 vs 对照14.4个月,作者认为在未筛选肿瘤HA状态的患者中加入PEGPH20似乎有害。

要点

  • II期剂量为PEGPH20每2周3 µg/kg,较I期每周两次方案更可耐受。
  • 中期无效分析时35例死亡(103例可分析患者)显示OS HR 2.07 favoring对照臂,研究停止入组。
  • 联合组治疗相关3-4级毒性显著增加(OR 2.7,95%CI 1.1-7.1),中位OS 7.7个月 vs 对照14.4个月。

核心结论

  • 在未筛选肿瘤HA状态的患者中,mFOLFIRINOX联合PEGPH20似乎有害,联合组毒性增加(主要为胃肠道和血栓栓塞事件)且治疗持续时间缩短。
  • mFOLFIRINOX对照臂中位OS为14.4个月(95%CI 10.1-15.7个月),据作者所知为迄今报告最长,可考虑用于体能状态好的患者。

研究设计与样本

  • IB/II期随机研究SWOG S1313,纳入未经治疗的转移性胰腺癌患者,体能状态0-1分,器官功能充分,入组不要求肿瘤HA状态。
  • IB期剂量探索后进入II期开放标签随机(1:1)研究,共138例,比较mFOLFIRINOX联合PEGPH20组与mFOLFIRINOX单药组,主要终点为总生存期。

主要发现

  • PEGPH20每2周3 µg/kg较I期每周两次方案更可耐受,故定为II期剂量。
  • 因血栓栓塞事件增加,研究修订在PEGPH20联合组加入依诺肝素预防。
  • 35例死亡(103例可分析患者)时进行的中期无效分析显示OS风险比2.07,favoring对照臂,研究停止入组。
  • 联合组治疗相关3-4级毒性较对照显著增加(OR 2.7,95%CI 1.1-7.1)。
  • mFOLFIRINOX单药组中位OS为14.4个月(95%CI 10.1-15.7个月),联合PEGPH20组为7.7个月(95%CI 4.6-9.3个月)。

临床怎么用

  • 作者认为,在未筛选肿瘤HA状态的患者中,mFOLFIRINOX联合PEGPH20似乎有害。
  • 作者指出,mFOLFIRINOX对照臂中位OS 14.4个月可考虑用于体能状态好的患者。

局限性

  • 研究因中期无效分析显示OS风险比2.07 favoring对照臂而提前停止入组。
  • 联合组治疗相关3-4级毒性显著增加(OR 2.7,95%CI 1.1-7.1)。
  • 联合组血栓栓塞事件增加,需加入依诺肝素预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pegylated recombinant human hyaluronidase (PEGPH20) degrades hyaluronan (HA) and, in combination with chemotherapy, prolongs survival in preclinical models. The activity of PEGPH20 with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) was evaluated in patients with metastatic pancreatic cancer (mPC). MATERIALS AND METHODS: Patients had untreated mPC, a performance status of 0 to 1, and adequate organ function. Tumor HA status was not required for eligibility. After a phase Ib dose-finding study of mFOLFIRINOX plus PEGPH20, the phase II open-label study randomly assigned patients (1:1) to the combination arm or to mFOLFIRINOX alone (n = 138). The primary end point was overall survival (OS). RESULTS: PEGPH20 dosages of 3 µg/kg every 2 weeks were more tolerable than twice-weekly dosages used in the phase I study, so 3 µg/kg every 2 weeks was the phase II dosage. An amendment instituted enoxaparin prophylaxis in the PEGPH20 combination arm as a result of increased thromboembolic (TE) events. The planned interim futility analysis when 35 deaths (of 103 analyzable patients) occurred resulted in an OS hazard ratio (HR) of 2.07 that favored the control arm, and the study was closed to accrual. The treatment-related grade 3 to 4 toxicity was significantly increased in the PEGPH20 combination arm relative to control (odds ratio, 2.7; 95% CI, 1.1 to 7.1). The median OS in the mFOLFIRINOX arm was 14.4 months (95% CI, 10.1 to 15.7 months) versus 7.7 months (95% CI, 4.6 to 9.3 months) in the PEGPH20 combination arm. CONCLUSION: Addition of PEGPH20 to mFOLFIRINOX seems to be detrimental in patients unselected for tumor HA status. This combination caused increased toxicity (mostly GI and TE events) and resulted in decreased treatment duration compared with mFOLFIRINOX alone. The median OS in the mFOLFIRINOX control arm (14.4 months) is, to our knowledge, the longest yet reported and can be considered for patients with good PS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ramanathan RK, McDonough SL, Philip PA, et al. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. J Clin Oncol. 2019. PMID: 30817250. doi:10.1200/JCO.18.01295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。